Imatinib mesylate is a selective tyrosine receptor kinase inhibitor with activity in chronic myelogenous leukemia (CML), Philadelphia chromosome–positive acute lymphoblastic leukemia, and gastrointestinal stromal tumors.[1][1]-[3][2] There is early evidence that it can reduce the phlebotomy
No takes yet. Share an insight, caveat, or question.
Lin et al. (2003) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: